ReviewMolecular cancer2026
Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrative RNA-Seq Analysis Reveals Stress Type-Dependent lncRNA-Centered Co-Expression Networks Across Human Cellular Stress Contexts.International journal of molecular sciences · 2026Article
- CircPRKCA Promotes NSCLC Progression via miR-200b-3p/FRMD6/SNAI2 Axis.International journal of molecular sciences · 2026Article
- Review
- Circular RNAs as molecular bridges: dual regulation of ferroptosis and immunity in cancer.Frontiers in immunology · 2026Review
- Epigenetics: the master switch of nasopharyngeal carcinoma invasion and metastasis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Precision oncology has transformed cancer care by tailoring treatments to individual molecular profiles, but many patients still fail to benefit from current therapies. In this context, biomarkers, particularly those measurable in non-invasive liquid biopsies, offer a promising path toward more effective and dynamic therapeutic strategies. Traditionally, circulating tumor DNA (ctDNA) has guided therapeutic decisions, but its limitations in capturing tumor complexity are becoming increasingly apparent. Conversely, non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) are emerging as powerful biomarkers due to their stability in all body fluids and their dynamic regulation in response to treatment. Encapsulated in extracellular vesicles (EVs) or associated with protein/lipid complexes, circulating ncRNAs are released by both tumor and microenvironmental cells, offering a unique biological insight. This review highlights the unique potential of ncRNAs as longitudinal biomarkers for monitoring therapeutic responses, detecting recurrence, and personalizing cancer management in real time, marking the beginning of a new era in precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.